

FCN - FranceCoag Network

Head :Goulet Véronique, Département des maladies chroniques et traumatismes

Last update : 05/13/2015 | Version : 1 | ID : 60

General

Identification

Detailed name FranceCoag Network

Sign or acronym FCN

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL authorisation no.: 903272

General Aspects

Medical area Hematology
Rare diseases

Pathology (details) hereditary hemorrhagic diseases (except platelet disorders)

Health determinants Genetic
Geography
Medicine

Keywords haemophilia, von Willebrand disease, national registry, inhibitor, hereditary hemorrhagic diseases, replacement therapy; prophylaxis

Scientific investigator(s) (Contact)

Name of the director Goulet

Surname Véronique

Address 12, rue du Val d'Osne 94415 Saint-Maurice

Phone + 33 (0)1 55 12 53 09

Email v.goulet@invs.sante.fr

Unit Département des maladies chroniques et traumatismes

Organization	INVS - Institut de Veille Sanitaire
--------------	-------------------------------------

Collaborations

Participation in projects, networks and consortia	Yes
---	-----

Details	Participation in the World Federation of hemophilia (WFH)
---------	---

Funding

Funding status	Public
----------------	--------

Details	Ministry of Health
---------	--------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	INVS - Institut de Veille Sanitaire
---	-------------------------------------

Organisation status	Public
---------------------	--------

Additional contact

Main features

Type of database

Type of database	Morbidity registers
------------------	---------------------

Study databases (details)	Cohort study
---------------------------	--------------

Additional information regarding sample selection.	None because of national registry.
--	------------------------------------

Database objective

Main objective	Four objectives: 1) Thorough knowledge of the epidemiological characteristics of hereditary haemorrhagic diseases ; 2) To monitor the health of this population; 3) To know the risk factors of inhibitor's development (treatment side effect) and their therapeutic management; 4) To assess the impact of preventive treatment and contribute to improving the quality of healthcare.
----------------	--

Inclusion criteria	Patients with: - Hemophilia A or B with factor VIII (FVIII) or factor (FIX) <40%;
--------------------	--

- Type 1 von Willebrand disease (VWD) with VWF:Ag <30%; Type 2 with a VWF:RCo/VWF:Ag ratio <0.7 or VWF:CB/VWF:Ag <0.7 or FVIII:C/VWF:Ag < 0.5 or positive RIPA; Type 3 with VWF:Ag and VWF:RCo <5%;
- Afibrinogenemia (fibrinogen < 0.2 g / l);
- a deficiency in factor FII, FV, FVII, FX, FXIII <10%, FXI <20% or FV + FVIII <30%.

Population type	
Age	Newborns (birth to 28 days) Infant (28 days to 2 years) Early childhood (2 to 5 years) Childhood (6 to 13 years) Adolescence (13 to 18 years) Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Male Woman
Geography area	National
Detail of the geography area	Patients are included throughout the national territory and monitored by 36 haemophilia treatment centres (HTC).
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	1994
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	9,288 patients enrolled on 07/09/2015.
Data	
Database activity	Current data collection
Type of data collected	Clinical data

	Paraclinical data Biological data
Clinical data (detail)	Medical registration
Paraclinical data (detail)	Score PedNet (joint score)
Biological data (detail)	Deficient factor base rate, inhibitor research assessment, etc.
Presence of a biobank	Yes
Contents of biobank	Serum Plasma Blood cells isolated
Details of biobank content	A Biobank was established between 1994 and 2002 and between 2008 and 2011. This includes blood samples (mononuclear cells, plasma, serum). The Biobank was stopped at the end of 2011.
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services Others
Care consumption (detail)	Medicines consumption
Other (detail)	Genetics, ethnic origin
Procedures	
Data collection method	Data are gathered through electronic forms by clinicians following patients in 36 haemophilia treatment centres throughout the national territory.
Classifications used	Coding conventions specific to project.
Quality procedure(s) used	Data monitoring conducted by 3 clinical research associates. Data are checked: - at the coordination centre by automatically processing collected data after recording (missing data, outliers and inconsistent data) - in treatment centres against clinical files on 100% of forms: General cohort (on a selection of items); PUPS sub-cohort (all data).
Participant monitoring	Yes
Details on monitoring of participants	No follow-up schedule imposed by clinicians; No controlled treatment; No specific examination; Only one recommendation: patient's data sent on an annual (general cohort) or quarterly basis (PUPS sub-cohort = patients with severe hemophilia).

Links to administrative sources	No
---------------------------------	----

Promotion and access

Promotion

Link to the document	http://www.francecoag.org/SiteWebPublic/html/documentsTele.html
----------------------	---

Access

Terms of data access (charter for data provision, format of data, availability delay)

Access to operation results on the database through webFC, dedicated RFC computer application (<http://www.francecoag.org>). Database is accessible to all internal or external researchers interested in the project after submitting a project to 2 experts that is validated by members of the RFC Steering Committee.